Suppr超能文献

G蛋白偶联受体的内源性变构调节剂

Endogenous allosteric modulators of G protein-coupled receptors.

作者信息

van der Westhuizen Emma T, Valant Celine, Sexton Patrick M, Christopoulos Arthur

机构信息

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia.

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia

出版信息

J Pharmacol Exp Ther. 2015 May;353(2):246-60. doi: 10.1124/jpet.114.221606. Epub 2015 Feb 3.

Abstract

G protein-coupled receptors (GPCRs) are the largest superfamily of receptors encoded by the human genome, and represent the largest class of current drug targets. Over the last decade and a half, it has become widely accepted that most, if not all, GPCRs possess spatially distinct allosteric sites that can be targeted by exogenous substances to modulate the receptors' biologic state. Although many of these allosteric sites are likely to serve other (e.g., structural) roles, they nonetheless possess appropriate properties to be serendipitously targeted by synthetic molecules. However, there are also examples of endogenous substances that can act as allosteric modulators of GPCRs. These include not only the obvious example, i.e., the G protein, but also a variety of ions, lipids, amino acids, peptides, and accessory proteins that display different degrees of receptor-specific modulatory effects. This also suggests that some GPCRs may possess true "orphan" allosteric sites for hitherto unappreciated endogenous modulators. Of note, the increasing identification of allosteric modulator lipids, inflammatory peptides, and GPCR-targeted autoantibodies indicates that disease context plays an important role in the generation of putative endogenous GPCR modulators. If an endogenous allosteric substance can be shown to play a role in disease, this could also serve as an impetus to pursue synthetic neutral allosteric ligands as novel therapeutic agents.

摘要

G蛋白偶联受体(GPCRs)是人类基因组编码的最大的受体超家族,也是目前最大的一类药物靶点。在过去十五年里,人们已广泛接受这样的观点:即便不是全部,大多数GPCRs都拥有空间上不同的变构位点,外源性物质可作用于这些位点来调节受体的生物学状态。尽管许多这些变构位点可能还具有其他(如结构)功能,但它们仍具备被合成分子意外作用的合适特性。然而,也有内源性物质可作为GPCRs变构调节剂的例子。这不仅包括明显的例子,即G蛋白,还包括各种离子、脂质、氨基酸、肽和辅助蛋白,它们表现出不同程度的受体特异性调节作用。这也表明,一些GPCRs可能拥有真正的“孤儿”变构位点,用于尚未被认识的内源性调节剂。值得注意的是,变构调节剂脂质、炎性肽和靶向GPCR的自身抗体越来越多地被发现,这表明疾病背景在推定的内源性GPCR调节剂的产生中起着重要作用。如果一种内源性变构物质能被证明在疾病中起作用,这也可以推动人们去寻找合成中性变构配体作为新型治疗药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验